公开(公告)号：US20220289679A1

公开(公告)日：2022-09-15

申请号：US17630442

申请日：2020-07-28

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Yuta TANAKA ,  Yuta TANAKA ,  Keiko KAKEGAWA ,  Takahito KASAHARA ,  Fumiaki KIKUCHI ,  Takeshi YAMAMOTO ,  Tomohiro OHASHI ,  Zenichi IKEDA ,  Florian PUENNER ,  Minoru NAKAMURA ,  Kazuaki TAKAMI ,  Masataka MURAKAMI ,  Masaki DAINI ,  Masaki SETO ,  Satoshi MIKAMI ,  Minoru SASAKI

IPC: C07D213/82 ,  C07D401/12 ,  C07D471/04 ,  C07D413/12 ,  C07D405/14 ,  C07D401/14 ,  C07D237/14 ,  C07D405/12

Abstract: The present invention provides a compound having a glucosylceramide synthase inhibitory action, which is expected to be useful as an agent for the prophylaxis or treatment of lysosomal storage diseases (e.g., Gaucher's disease, Fabry's disease, GM1-gangliosidosis, GM2 activator deficiency, Tay-Sachs disease, Sandhoffs disease), neurodegenerative diseases (e.g., Parkinson's disease, Lewy body dementia, multiple-system atrophy) and the like.
The present invention relates to a compound represented by the formula (I): wherein each symbol is as described in the description, or a salt thereof.

公开(公告)号：US20220089525A1

公开(公告)日：2022-03-24

申请号：US17310164

申请日：2020-01-23

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Yuya OGURO ,  Makoto KAMATA ,  Satoshi MIKAMI ,  Shinji MORIMOTO ,  Sachie TAKASHIMA ,  Masaki DAINI ,  Osamu KUBO ,  Fumiaki KIKUCHI ,  Akinori TOITA ,  Florian PUENNER ,  Takahito KASAHARA ,  Masataka MURAKAMI ,  Shuhei IKEDA ,  Fumie YAMAGUCHI ,  Minoru NAKAMURA ,  Takafumi YUKAWA

IPC: C07C255/60 ,  C07D213/82 ,  C07D401/12 ,  C07D409/12 ,  A61P25/06 ,  A61P25/24 ,  A61P25/28 ,  A61P29/00

Abstract: A heterocyclic compound that can have an antagonistic action on an NMDA receptor containing the NR2B subunit, and is expected to be useful as a prophylactic or therapeutic agent for depression, bipolar disorder, migraine, pain, peripheral symptoms of dementia and the like is provided. A compound represented by the formula (I): wherein each symbol is as described in the DESCRIPTION, or a salt thereof.

公开(公告)号：US20220274982A1

公开(公告)日：2022-09-01

申请号：US17630840

申请日：2020-07-28

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Yuta TANAKA ,  Yuta TANAKA ,  Fumiaki KIKUCHI ,  Takeshi YAMAMOTO ,  Minoru NAKAMURA ,  Kazuaki TAKAMI ,  Masataka MURAKAMI ,  Masaki DAINI ,  Yasufumi WADA ,  Keiko KAKEGAWA ,  Takahito KASAHARA ,  Tomohiro OHASHI ,  Junsi WANG ,  Zenichi IKEDA ,  Florian PUENNER ,  Masaki SETO ,  Satoshi MIKAMI ,  Minoru SASAKI

IPC: C07D471/04

Abstract: The present invention provides a compound having a glucosylceramide synthase inhibitory action, which is expected to be useful as an agent for the prophylaxis or treatment of lysosomal storage diseases (e.g., Gaucher's disease, Fabry's disease, GM1-gangliosidosis, GM2 activator deficiency, Tay-Sachs disease, Sandhoffs disease), neurodegenerative diseases (e.g., Parkinson's disease, Lewy body dementia, multiple-system atrophy) and the like.
The present invention relates to a compound represented by the formula (I): wherein each symbol is as described in the description, or a salt thereof.